PD-L1-Targeting Lipid Nanoparticles
Northwestern researchers developed PD-L1-targeting lipid nanoparticles to directly neutralize or eliminate immunosuppressive cells in the tumor.
Discover Intellectual Property
Explore groundbreaking oncology technologies from leading universities. These innovations are unlicensed, untapped, and ready to become the next big biotech breakthrough.
Recent additions
Minibinder-Drug Conjugates
University of Washington’s minibinder-drug conjugates are ultra-stable, computationally designed proteins fused to cytotoxic payloads; potentially superior to traditional ADCs.
STING-Peptide Vaccine Fusion Protein
MIT: A soluble STING-peptide vaccine fusion protein that traffics to lymph nodes, delivering simultaneous antigen presentation and immune activation.
